

Pending Claims:

1.-14. (cancelled).

15. (previously presented) A method for treatment of rheumatoid arthritis comprising administering to a subject suffering from rheumatoid arthritis a therapeutically effective amount of an antibody molecule comprising antigen binding regions derived from the light and heavy chain variable regions of an antibody to an $\alpha 1\beta 1$ integrin or fragment thereof.

16. (previously presented) A method for inhibiting or preventing rheumatoid arthritis comprising administering to a subject at risk of developing or suffering from rheumatoid arthritis a therapeutically effective amount of an antibody molecule comprising antigen binding regions derived from the light and heavy chain variable regions of an antibody to an $\alpha 1\beta 1$ integrin or fragment thereof.

17. (previously presented) A method of claim 15, wherein the antibody is AJH10 secreted by a hybridoma designated as ATCC PTA-3580.

18. (previously presented) A method of claim 16, wherein the antibody is AJH10 secreted by a hybridoma designated as ATCC PTA-3580.

19. (previously presented) A method of claim 15, wherein the antibody is a human antibody, a chimeric antibody, a humanized antibody, a monoclonal antibody, or a polyclonal antibody.

20. (previously presented) A method of claim 16, wherein the antibody is a human antibody, a chimeric antibody, a humanized antibody, a monoclonal antibody, or a polyclonal antibody.

21. (previously presented) A method of claim 15, wherein the antibody is an anti- $\alpha 1$ -I domain blocking antibody and the amino acid sequence of the antibody epitope comprises the sequence Val-Gln-Arg-Gly-Gly-Arg (SEQ ID NO: 8) or an amino acid sequence that is equivalent or homologous to such sequence.

22. (previously presented) A method of claim 16, wherein the antibody is an anti- $\alpha 1$ -I domain blocking antibody and the amino acid sequence of the antibody epitope

comprises the sequence Val-Gln-Arg-Gly-Gly-Arg (SEQ ID NO: 8) or an amino acid sequence that is equivalent or homologous to such sequence.

23. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of the antibody AJH10 secreted by a hybridoma designated as ATCC PTA-3580 effective in preventing, inhibiting, or treating rheumatoid arthritis.